Brings a wealth of financial leadership from world-class organizations such as Honeywell and PfizerSOMERSET, N.J., Oct. 09, 2025 (GLOBE NEWSWIRE) -- CompoSecure, Inc. (NYSE: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced the appointment of Mary Holt as Chief Financial Officer (CFO), effective the day immediately following the filing of the Company's Q3 2025 Quarterly Report. She succeeds Tim Fitzsimmons who is retiring after a distinguished career with the co ...

Financial Data and Key Metrics Changes - The company reported 3% organic growth in Q2, with life sciences slightly above that in the mid-single-digit range and diagnostics in the low single-digit range [4][5] - The guidance for the full year has been adjusted down to 2% to 4% organic growth, a decrease of 100 basis points primarily due to the impact of China diagnostics [44][70] - The company expects a significant sequential increase in Q4, projecting mid-single-digit growth driven by diagnostics, particularly from the OMICS contract with Genomics England [47][49] Business Line Data and Key Metrics Changes - The life sciences segment saw mid-single-digit growth, largely attributed to the Signals business, which grew over 30% [12][14] - The reagents business has shown consistent sequential growth for six straight quarters, with demand primarily driven by pharma [25][26] - The diagnostics business in China faced a 15% decline in Q2, with expectations of a mid-20% decline in the second half due to changes in reimbursement policies [7][8] Market Data and Key Metrics Changes - The company’s exposure to the China diagnostics market is about 9% of total revenue, with overall China contributing 15% to 16% of revenue [8][9] - The U.S. market for the company’s A&G segment is approximately 5% of the revenue base, with expectations of a similar market environment in the second half of the year [19][21] - The company anticipates continued growth in the life sciences sector in China, with mid-single-digit growth expected for the second half [23][24] Company Strategy and Development Direction - The company is focusing on expanding its software offerings and transitioning to a SaaS model, with a strong emphasis on customer retention and growth in annualized portfolio value [15][17] - The strategy includes increasing automation in the U.S. market to enhance competitiveness, particularly in the ImmunoDX business [37][38] - The company aims to leverage its competitive advantages in customer service and product quality to capture market share from competitors [29][30] Management's Comments on Operating Environment and Future Outlook - Management expressed cautiousness regarding the operating environment, particularly in the pharma sector, due to uncertainty in policies affecting investment planning [18][26] - The company remains optimistic about its margin expansion potential, projecting a baseline operating margin of 28% for 2026 despite current low single-digit growth expectations [55][57] - Management highlighted the importance of clarity in regulatory policies to drive growth and investment in the coming years [26][66] Other Important Information - The company has achieved a free cash flow conversion rate of 90% in the first half of the year, with expectations to maintain this trend moving forward [66][68] - Share buybacks have increased significantly, with the company planning to continue repurchasing shares at favorable prices [69][70] Q&A Session Summary Question: What is the outlook for organic growth in 2026? - Management indicated that while the market is expected to remain flat to slightly up, they anticipate growing a couple of hundred basis points above that, aiming for low single-digit growth [62][64] Question: How is the company addressing tariff impacts? - The company has operationally mitigated some tariff impacts, particularly from China, but expects to absorb some net costs moving forward [9][61] Question: What are the key competitive advantages in the reagents business? - Management believes their customer service, product quality, and market approach provide significant competitive advantages over peers [29][30]

Financial Data and Key Metrics Changes - Ambac reported a consolidated net loss of $548 million or $10.23 per diluted share for Q4 2024, compared to a net loss of $16 million or $0.24 per diluted share in Q4 2023 [28] - The consolidated adjusted net loss was $6 million or $0.12 per diluted share for Q4 2024, compared to adjusted net income of $4 million or $0.10 per diluted share in Q4 2023 [30] - The company recorded a $570 million loss on the sale of its legacy financial guarantee business, now reported as discontinued operations [23] Business Line Data and Key Metrics Changes - The P&C business generated nearly $900 million in premiums, up 74% from 2023, and produced $236 million in revenue, an increase of 89% from the prior year [7] - Cirrata generated nearly $100 million in revenue for 2024, up 93%, and earned approximately $20 million of adjusted EBITDA [15] - Everspan's gross premium written grew to over $380 million, up 40% from the prior year, with a combined ratio of 101.6%, improving nearly 500 basis points over 2023 [20][39] Market Data and Key Metrics Changes - The overall E&S market continues to perform well, with high-single to double-digit rate increases in U.S. casualty lines [12] - The property market showed some softening in Q4 2024, but terms and conditions have held [13] - Professional and financial lines are experiencing softness, particularly in large account and public market D&O [14] Company Strategy and Development Direction - The company is focused on the future growth of its Specialty P&C business and delivering value for shareholders [11] - Ambac aims to achieve strong organic growth and generate $80 million to $90 million of adjusted EBITDA to common shareholders by 2028 [44] - The acquisition of Beat is expected to deliver strong organic growth and enhance the distribution platform [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about stabilization in the Employer Stop Loss and short-term medical segments, despite current challenges [50][51] - The focus remains on profitability for Everspan, with effective loss ratios in the mid-60s aligning with long-term goals [55] - Management is excited about the prospects of Ambac's future and the unique value proposition it offers in the specialty MGA space [43] Other Important Information - The company has committed third-party capacity of more than $1.5 billion for 2025, with over 60% of that support being long-term [19] - The adjusted EBITDA margin for 2024 was 20%, with expectations for meaningful advancements in the future [15][16] Q&A Session Summary Question: Distribution business performance and outlook - Management noted softening in Employer Stop Loss and short-term medical segments, with expectations for stabilization in the near future [50][51] Question: Sustainability of Everspan's combined ratio - Management indicated that while there are variabilities, the performance aligns with long-term objectives, aiming for effective loss ratios in the mid-60s [55]